Rtw Investments Adds $16M in Ultragenyx Pharmaceutical Inc. ($RARE)
RTW Investments boosted its holdings in RARE by 21.6%, adding 648,656 shares.
Key Points
- RTW Investments increased its stake in RARE by 21.6%, adding 648,656 shares to reach a total of 3,648,795 shares, valued at approximately $88.3 million.
- RARE's stock is trading at $24.35, with a recent boost in institutional interest from major funds like BlackRock and Vanguard.
- Insider transactions include planned sales by executives and several analysts maintaining 'buy' ratings with varied price targets.
RTW Investments has boosted its stake in RARE by 21.6% according to its latest 13F filing with the SEC, adding 648,656 shares. This brings its total holdings to 3,648,795 shares, valued at about $88.3 million as of the reporting period ending May 15, 2026.
What Changed in RTW Investments' RARE Position
RTW Investments increased its investment in RARE significantly, adding 648,656 shares to its portfolio. This 21.6% increase brought its total holdings from 3,000,139 shares to 3,648,795 shares, reflecting a strong confidence in the company.
Other Institutional Activity in RARE
Other major funds also showed interest in RARE. BlackRock, Inc. grew its holdings by 668,044 shares, reaching a total of 7,299,598 shares valued at about $152.9 million. Vanguard Portfolio Management LLC maintained its position with 5,385,992 shares worth approximately $112.8 million. State Street Corp increased its stake by 718,395 shares, totaling 5,021,441 shares valued at $105.2 million. AQR Capital Management LLC made a substantial addition of 3,217,527 shares, bringing its total to 4,578,024 shares, valued at around $95.9 million.
RARE Stock Snapshot
RARE's shares are currently trading at $24.35. The company has seen a range of institutional interest and activity, suggesting a lively market presence. However, detailed fundamentals such as market cap and P/E ratio are not provided.
Insider Buying and Selling at Ultragenyx Pharmaceutical Inc.
Recent insider activity at RARE includes several transactions. On June 1, 2026, Howard Horn, the Chief Financial Officer, sold 4,653 shares at an average price of $23.77 under a planned sale. On May 18, 2026, Shehnaaz Suliman sold 5,740 shares at $25.12, also under a planned sale. On May 14, 2026, insiders including Shehnaaz Suliman, Amrit Ray, and Michael Narachi made unplanned purchases totaling 39,618 shares.
Analysts Set New Price Targets
Analysts have been active with RARE. On May 21, 2026, Cantor Fitzgerald maintained a 'buy' rating with a price target of $96. Guggenheim also maintained a 'buy' rating with a $43 target on May 8, 2026. Wells Fargo kept its 'buy' rating with a $47 target on May 6, 2026, while Wedbush held a 'hold' rating with a $26 target. The consensus among analysts remains positive with a mix of 'buy' and 'hold' ratings.
About RARE
RARE operates in the biotechnology sector, focusing on developing therapies for rare diseases. The company aims to address unmet medical needs through innovative treatments. Headquartered in the United States, RARE is committed to advancing its pipeline of therapies to improve patient outcomes.
Bottom Line
RTW Investments' increased stake in RARE reflects a strong vote of confidence in the company's prospects. While the 13F filing provides a snapshot of past holdings, it underscores the ongoing interest from institutional investors. As always, these filings are backward-looking and may not represent the current position of the investor.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.